Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy and safety of prophylaxis of venous thromboembolism by Nadroparin during hospitalization to long-term usage in patients with advanced lung cancer treated by chemotherapy and/or radiotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shengqing Li
• Treatments: Nadroparin

Criteria

Inclusion Criteria:

• Stage Ⅲ B and Ⅳ non-small cell lung cancer patients and inoperable small cell lung cancer patients

• Performance status score ≤ 2

• Chest CT with measurable lesions

Exclusion Criteria:

• Examination revealed any part of venous thromboembolism

• Chemotherapy regimens containing bevacizumab or Endostar

• Severe coagulopathy

• Active bleeding within two weeks